Robert W. Baird Has Lowered Expectations for Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price

Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) had its target price lowered by equities researchers at Robert W. Baird from $54.00 to $42.00 in a research report issued on Tuesday,Benzinga reports. The firm presently has an "outperform" rating on the stock.

Other equities analysts also recently issued reports about the stock. Royal Bank of Canada reiterated an "outperform" rating and set a $45.00 price objective on shares of Karyopharm Therapeutics in a research note on Thursday, February 20th. HC Wainwright upped their target price on Karyopharm Therapeutics from $7.00 to $56.00 and gave the stock a "buy" rating in a report on Wednesday, February 26th. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $43.20.

Karyopharm Therapeutics Stock Performance

KPTI traded down $0.12 during trading on Tuesday, hitting $5.32. 35,974 shares of the stock were exchanged, compared to its average volume of 82,243. Karyopharm Therapeutics has a 1 year low of $3.51 and a 1 year high of $17.85. The firm has a 50 day simple moving average of $5.37 and a 200 day simple moving average of $8.71. The firm has a market cap of $45.96 million, a price-to-earnings ratio of -5.22 and a beta of 0.33.

Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($2.77) earnings per share for the quarter, topping analysts' consensus estimates of ($4.21) by $1.44. The business had revenue of $30.02 million during the quarter, compared to analysts' expectations of $35.12 million. As a group, equities analysts anticipate that Karyopharm Therapeutics will post -0.71 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of KPTI. Velan Capital Investment Management LP purchased a new stake in Karyopharm Therapeutics during the fourth quarter valued at approximately $27,000. Focus Partners Wealth purchased a new stake in shares of Karyopharm Therapeutics during the 4th quarter valued at $31,000. TD Waterhouse Canada Inc. acquired a new stake in shares of Karyopharm Therapeutics in the 4th quarter worth $32,000. Two Sigma Advisers LP boosted its position in shares of Karyopharm Therapeutics by 145.5% in the 4th quarter. Two Sigma Advisers LP now owns 76,600 shares of the company's stock worth $52,000 after purchasing an additional 45,400 shares in the last quarter. Finally, Opti Capital Management LP purchased a new position in Karyopharm Therapeutics during the 4th quarter worth $85,000. Hedge funds and other institutional investors own 66.44% of the company's stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).